PMC5398113_01
Histopathology showing monomorphic epithelioid peritoneal mesothelioma, (H and E, x100)
IJMPO-38-73-g001.jpg
PMC5398113_01_IJMPO-38-73-g001.jpg
F1
Findings such as these are consistent with the diagnosis of a diffuse malignant peritoneal monomorphic epithelioid mesothelioma [Figures 1-5].
Calretinin-positive staining
IJMPO-38-73-g002.jpg
PMC5398113_01_IJMPO-38-73-g002.jpg
F2
Findings such as these are consistent with the diagnosis of a diffuse malignant peritoneal monomorphic epithelioid mesothelioma [Figures 1-5].
CK5/6 positive staining
IJMPO-38-73-g003.jpg
PMC5398113_01_IJMPO-38-73-g003.jpg
F3
Findings such as these are consistent with the diagnosis of a diffuse malignant peritoneal monomorphic epithelioid mesothelioma [Figures 1-5].
CD15 negative staining
IJMPO-38-73-g004.jpg
PMC5398113_01_IJMPO-38-73-g004.jpg
F4
Findings such as these are consistent with the diagnosis of a diffuse malignant peritoneal monomorphic epithelioid mesothelioma [Figures 1-5].
BerEP4 negative staining
IJMPO-38-73-g005.jpg
PMC5398113_01_IJMPO-38-73-g005.jpg
F5
Findings such as these are consistent with the diagnosis of a diffuse malignant peritoneal monomorphic epithelioid mesothelioma [Figures 1-5].
Radiological evaluation of diffuse malignant peritoneal mesothelioma with 18 (fludeoxyglucose) positron emission tomography-computed tomography scan performed 6 months after first-line chemotherapy. (a) Axial pelvic follow-up computed tomography demonstrates only fibrotic changes scattered throughout small bowel. (b) Axial abdominal follow-up computed tomography scan (intestine opacified with amidotrizoate) showing enlarged spleen, with smooth parietal peritoneal thickening. (c) Positron emission tomography-fused-axial chest computed tomography scan without signs of increased (18) fludeoxyglucose uptake in thoracic cavity. (d) Positron emission tomography-fused-axial abdominal computed tomography scan without detectable (18) fludeoxyglucose peritoneal uptakes
IJMPO-38-73-g006.jpg
PMC5398113_01_IJMPO-38-73-g006.jpg
F6
First follow-up scan, performed 6 months after first-line chemotherapy, showed stable intrathoracic and intra-abdominal disease [Figure 6a-d].